INAB - in8bio.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

IN8bio, Inc. (INAB) is developing cellular therapies for oncohematology, facing typical biotech risks regarding capital burn and clinical trial uncertainty. Diagnostic efficiency is driven by deep automation of laboratory sample analysis. The visualization of EV/EBITDA price dynamics is 0.00. Operational stability is maintained by outsourcing all research to external CRO contractors, which minimizes internal production disruptions.

INAB IN8bio, Inc: Company Value to EBITDA in the range 11/23/2025 - 11/11/2026

in8bio.com - analytical breakdowns and key metrics (INAB)

- current price and projected stock value:

Stock Price IN8bio, Inc|INAB - Price Target Chart

- market capitalization statistics:

Market Value IN8bio Inc|INAB - Total Company Value

- book value of equity indicators:

Net Assets per Single Share IN8bio|INAB - Total Stockholders' Equity|Market Value to Book Value Ratio in8bio.com|INAB - Company Assets

- business debt structure and liquidity details:

- business earnings and investment ratios data:

INAB - Net Profit|Company Profit Forecast IN8bio, Inc.|INAB - Price to Earnings Ratio|Projected Price to Earnings Ratio IN8bio, Inc.|INAB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation IN8bio Inc|INAB - Operating profit EBITDA|Net earnings per share for the last four quarters IN8bio|INAB - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months in8bio.com|INAB - Earnings growth in current year|Expected earnings per share growth for next year IN8bio, Inc.

Comprehensive company analysis:INAB (IN8bio, Inc)

By outsourcing production and clinical trials, IN8bio, Inc. (INAB) minimizes capital expenditures, which directly impacts the profit calculation base. This metric compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, determining the payback period for assets. By analyzing the EV/EBITDA ratio in a historical context, an investor can distinguish fundamental undervaluation from a "value trap" during a decline in operational efficiency.

Competitor analysis for IN8bio, Inc.

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kura Oncology (KURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ADC Therapeutics S.A. (ADCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics, Inc.|Company Value to EBITDA Vor Bio Inc. VOR|EV/EBITDA Multiple NKTX|coeptistx.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATNM (Actinium Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Estrella Immunopharma Inc (ESLA)|CASI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MRKR (Marker Therapeutics) - Enterprise Value to Operating Income Before Depreciation|Business Value to Operating Income Before Depreciation eternatx.com ERNA|gtbiopharma.com (GTBP) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptose Biosciences Inc|EV/EBITDA Multiple Bio-Path Holdings Inc.|MEIP (MEI Pharma Corp) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VINC (vincerx.com)